To investigate the role of radiotherapy (RT) for upper urinary tract urothelial cell carcinoma (UTUC) after surgery.
urinary tract cancers. (2) Usually, patients with UTUC are treated with radical surgery, and radiotherapy (RT) has not had an established role. Local-regional control of T1 to T3 stage disease is excellent in surgical series, (3, 4) and isolated local recurrence is rare. (5) Bladder and distant recurrences are the most common pattern of first recurrence. (3, 6) Thus, adjuvant RT does not provide much benefit for most patients in theory. Past studies that examined the benefits of adjuvant RT also have not consistently supported the usage of postoperative RT. For example, Cozad and colleagues reported significant improvement in local control, and marginal improvement in the overall survival (OS). (7) Another report, by Maulard-Durdux et al., showed that adjuvant RT did not provide any benefit at all. (8) Hall and colleagues also reported that adjuvant RT had no positive effect. (9) Therefore, adjuvant RT is not a routine treatment at the present time. However, there are some questions about this conclusion. First, recurrence patterns may vary with stage. Most surgical series showed local-regional recurrence without stratification by stage or other risk factors. Actually, local-regional recurrence is similar to distant metastasis in patients with a high risk of recurrence. (10) Many studies did not include routine computed tomography (CT) or magnetic resonance imaging (MRI) to detect asymptomatic recurrence during follow-up. (5) Local-regional recurrence might be missed. Second, studies which had negative results used old RT techniques. The prescribed dose of RT, which was limited by normal organ tolerance, was usually suboptimal. Thus, an out-of-date RT technique would result in inadequate tumor control. (6, 8) Moreover, it may cause excess damage to healthy organs, and offset the benefits of RT.
For recurrent UTUC, chemotherapy is the most common salvage treatment. However, isolated local or regional recurrence does occur in some of our patients. Local irradiation is applied in these patients, but the effectiveness of salvage RT is unknown, because clinical results for reference are lacking.
To solve these two questions, we performed this retrospective study to analyze treatment outcomes of adjuvant and salvage RT after surgery. Furthermore, this study may provide useful information for physicians who have encountered these uncommon indications for radiotherapy.
METHODS
This study included 40 patients with UTUC who received radical surgery and RT in our hospital from July 1997 to February 2007. All patients had a good performance status and had received radical surgery as the primary treatment. Among the 40 patients, 20 had adjuvant RT for positive resection margins or advanced disease (PORT). The remainder had RT as salvage treatment (SART) for local-regional recurrence. Patients who had metastatic disease or histology other than urothelial carcinoma, or who had received short-term palliative RT were excluded from this study.
Tumor staging was pathologic staging for the PORT group and clinical staging for the SART group. It followed the American Joint Committee on Cancer staging criteria; staging results were revised according to the 2002 staging system. (11) In addition, we recorded the status of the surgical margins, method and conditions of lymph node dissection, the degree of histologic differentiation, the site of origin, laterality, perineural invasion, and lymphatic permeation in the PORT group. The patient characteristics of each group are listed in Table 1 .
The prescription dose of RT ranged from 32 to 66.6 Gy (median: 50 Gy), with 1.8 or 2 Gy in one fraction per day, 5 days per week. All patients were treated with 3-D conformal radiotherapy or intensitymodulated radiotherapy. For the PORT group, the clinical target volume (CTV) included the tumor bed and paraaortic nodal area. For the SART group, the CTV was an expansion of the gross tumor, which covered the microscopic extension of the tumor. The expansion from the CTV to the planning target volume (PTV) was around 1cm in 3 dimensions, and modified by the physician individually. The minimal doses delivered to the CTV and PTV were 100% and 95% of the prescription dose. respectively, while the maximal dose could not exceed 110% of the prescription dose. Chemotherapy had been given to 34 patients in varied regimens and combinations with RT. Twenty-six patients had received concurrent and adjuvant cisplatin-based chemotherapy. Eight patients had received similar regimens of chemotherapy only after radiotherapy.
After RT, patients were followed regularly in the outpatient department. Image evaluation such as CT scans and chest radiographs were done every 6 to 12 months or when there was any sign of tumor recurrence. If tumor recurrence was detected, it was proved by biopsy or at least 2 examinations. The type of recurrence was determined by the records of the radiologist or primary care doctor. Generally, recurrence at the retroperitoneal space around the renal fossa was defined as local recurrence. Nodal recurrence in the paraaortic region was defined as regional recurrence. If another tumor developed in the rest of urinary tract, it was recorded as a second urinary tract cancer rather than progression of the tumor. Tumor recurrence outside the above region was defined as distant metastasis. The primary endpoint was disease progression. Death was another endpoint of this study. Survival was dated from the end of RT. The median follow-up time was 20 months (1 -93 months).
For incidence of event, Pearson's chi-quare test and Fisher's exact test were used to determine the significance of difference. For survival analysis, we used the Kaplan-Meier method and the log-rank test to determine the significance of differences between endpoints of different patients. The Cox regression model was used to perform multivariate analysis. The relation of each variable to the endpoints was compared with both univariate and multivariate analysis. Differences were considered significant when the p value was less than 0.05. We used the commercial statistics package SPSS 11.0 (SPSS Inc., Chicago, IL, U.S.A.).
RESULTS
At the time of analysis, 9 patients were still alive, but two of them had tumor recurrence. Twenty-five patients died from recurrent disease. Two patients (one in each group) died from chemotherapy-related complications, and two from non-cancer comorbidities. Two patients were lost to follow-up, and one of them had tumor recurrence.
The 3-year overall survival OS was 45% for the PORT group, and 16% for the SART group (p = 0.03). The median OS was 29 months and 15 months (p = 0.03), and the 3-year progression-free survival (PFS) was 41% and 12% (p = 0.02), respectively. The median OS was 28 months and 15 months. And the median PFS was 21 months and six months, respectively.
Tumors recurred in 29 patients. Distant metastasis was the first recurrence in 17 patients, and localregional recurrence was the first recurrence in 11 patients. One patient had bladder cancer as the only cancer event after completion of adjuvant radiotherapy. A total of four patients developed a second urinary tract cancer during follow-up. The failure pattern was similar in the PORT and SART groups. Local -regional failure occurred as the first recurrence in three patients in the PORT group (15%), and in six in the SART group (30%, Fisher's exact test: p = 0.273). Distant failure was the first tumor recurrence in nine patients in the PORT group (45%) and eight in the SART group (40%, chi-square test: p = 0.855).
In univariate analysis, a prescription dose < 50 Gy (p = 0.02), and SART (p = 0.04) were significant prognostic factors for the OS ( Fig. 1 and 2 ) and PFS. The 3-year OS increased from 18% to 38% (p = 0.06) if the prescription dose was ≥ 50 Gy. The median OS increased from 15 months to 28 months, as well. The 3-year PFS with a prescription dose ≥ 50 Gy was 41%, and 7% with a prescription dose < 50 Gy (p < 0.05). The median PFS was prolonged from 6 months to 21 months when the prescription dose was ≥ 50 Gy. The detailed dose response of different groups is listed in Table 2 . In multivariate analysis, SART was the only independent factor for OS (p = 0.02), and the prescription dose was the only independent factor for PFS (p = 0.02) ( Table 3) .
DISCUSSION
Currently, treatment of advanced UTUC is a difficult task. The PFS and OS are both poor, and there is no solid evidence to support the role of adjuvant treatment. However, we found several intriguing issues during a review of the literature. Most studies involving radical surgery did not report the localregional recurrence rates of different stages of disease in detail. (3, 5, 6) In studies which described recurrence patterns, local-regional recurrence rates were relatively higher with certain specific conditions, such as extensive parenchymal invasion or residual tumor. (4, 12) High grade tumors also correlated with a higher local recurrence rate. (3) In addition, evaluation with CT or MRI during follow-up was usually elective or not mentioned. (5, 6, 13) Isolated local-regional relapses might be missed without regular image examination. Li and colleagues reported local recurrence rates of 31% and 12% for pathologic T4 and T3 disease with abdominal CT scan applied during follow-up. With specification of risk factors and routine evaluation of modern image examinations, it is possible to identify a group of patients with a significantly higher local-regional recurrence rate. Adjuvant RT may provide benefits for them.
Although it is rare and the evidence strength is poor, there is some evidence supporting the role of adjuvant RT. (7, 12) Studies that did not support adjuvant radiotherapy used old RT techniques, and thus, the benefits of adjuvant RT could be offset by complications. (6, 8) In addition, the median prescription dose, which was 45 Gy in one study and 39.8 Gy in another, was relatively low. Technical and dose issues might be the reasons why adjuvant RT was ineffective in those studies. One retrospective study showed good clinical outcomes after postoperative RT with a median dose of 46.9 Gy. The five-year actuarial OS was 39%. (14) Our study showed similar results, with a 3-year OS of 46%, comparable with the outcome of advanced disease in a surgery series. (5) The localrecurrence rate of the PORT group was 15% in our study, which is better than in some surgical series which described local-regional recurrence in results. (3, 7, 12) Thus, postoperative RT should be effective in patients with a high risk of local recurrence, such as residual, pathologic T4, or high grade tumors.
Salvage treatment for local-regional recurrence is another tough problem. For metastatic urothelial carcinoma, a cisplatin-based combination regimen has a median survival of up to 16 months. (15) (16) (17) Second-line chemotherapy with a variable regimen has a median PFS of approximately 4 months, and an OS of up to 9 months; (18) (19) (20) however, reports of salvage treatment for isolated local-regional recurrence are rare. Local-regional recurrence causes severe pain that is difficult to relieve by medication or chemotherapy. Local irradiation is another choice to relieve symptoms and prolong PFS. Our study showed a median PFS of 6 months in the SART group. Two of 10 patients who received a dose ≥ 50 Gy remained progression-free after 3 years. Therefore, local irradiation with a dose of more than 50 Gy should be considered when isolated local- regional recurrence is found. Out study suggests a radiation dose response; both the OS and PFS were increased with a higher dose. Formerly, the radiation dose was usually limited to 45 Gy or less to prevent severe damage to abdominal organs. With the invention of new radiotherapy techniques, delivering a radiation dose more than 50 Gy is now possible. Several studies have reported clinical experience with radiotherapy with a prescription dose > 50 Gy in the abdominal region. The toxicity was tolerable, for both cancer in the abdominal region and para-arotic nodal metastasis. (21) (22) (23) So, if patients are to receive RT for UTUC, a prescription dose ≥ 50 Gy with a novel RT technique is recommended. This modality can effectively delay disease progression and prolong OS.
In conclusion, our study represents a series of adjuvant and salvage RT for UTUC. For adjuvant treatment, RT reduced disease recurrence with a higher prescription dose. For salvage treatment of local-regional recurrence, long-term survival is possible. It seems that RT combined with chemotherapy is effective for adjuvant or salvage treatment for advanced and recurrent UTUC. According to our analysis, the prescription dose should be ≥ 50 Gy for both adjuvant and salvage RT. Although long-term survival can be achieved, the overall treatment result is poor. Investigation of novel effective treatments is needed.
